Tags

Type your tag names separated by a space and hit enter

GnRH-agonist ovulation trigger in patients undergoing controlled ovarian hyperstimulation for IVF with ultrashort flare GnRH-agonist combined with multidose GnRH-antagonist protocol.
Gynecol Endocrinol. 2013 Jan; 29(1):51-3.GE

Abstract

OBJECTIVE

To evaluate, whether Gonadotropin-releasing hormone-agonist (GnRH-agonist or GnRH-ag) trigger in patients undergoing the ultrashort GnRH-ag/GnRH-antagonist (GnRH-ant) protocol is as effective as in patients at high risk to develop severe ovarian hyperstimulation syndrome (OHSS), who undergo the multidose GnRH-ant protocol.

DESIGN

Cohort study.

SETTING

University hospital.

PATIENTS

All consecutive women aged ≤35 years admitted to our IVF unit from January 2011 to October 2011 who reached the ovum pick-up stage.

INTERVENTIONS

Triggering final oocytes maturation by GnRH-ag instead of hCG, in high-responder patients undergoing either the ultrashort GnRH-ag/GnRH-ant or the multidose GnRH-antagonist controlled ovarian hyperstimulation (COH) protocols.

MAIN OUTCOME MEASURES

Ovarian stimulation characteristics, percentage of mature oocytes, fertilization and pregnancy rates.

RESULTS

No inbetween groups differences were observed in ovarian-stimulation related variable, percentage of mature oocytes, fertilization or pregnancy rates. No case of moderate-severe OHSS was reported in the study, or the control groups.

CONCLUSIONS

Three consecutive doses of daily GnRH-ag administration at the beginning of ultrashort flare GnRH-ag/GnRH-ant COH protocol, did not interfere with the ability of the GnRH-ag to trigger final oocytes maturation at the end of the COH cycle.

Links

Publisher Full Text

Authors+Show Affiliations

Orvieto R
Department of Obstetrics and Gynecology, Barzilai Medical Centre, Ashkelon, Israel. raoulo@barzi.health.gov.il
Nahum R
No affiliation info available
Zohav E
No affiliation info available
Liberty G
No affiliation info available
Anteby EY
No affiliation info available
Meltcer S
No affiliation info available

MeSH

AdultCohort StudiesDatabases, FactualFemaleFertilizationFertilization in VitroGonadotropin-Releasing HormoneGonadotropinsHumansInfertility, FemaleLuteolytic AgentsOocytesOvarian Hyperstimulation SyndromeOvulationOvulation InductionPregnancyPregnancy RateRisk FactorsTriptorelin Pamoate

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22857268

Clinical Trial Links

Ultrashort GnRH Agonist/Antagonist Versus GnRH Antagonist IVF

Citation

Orvieto, Raoul, et al. "GnRH-agonist Ovulation Trigger in Patients Undergoing Controlled Ovarian Hyperstimulation for IVF With Ultrashort Flare GnRH-agonist Combined With Multidose GnRH-antagonist Protocol." Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, vol. 29, no. 1, 2013, pp. 51-3.
Orvieto R, Nahum R, Zohav E, et al. GnRH-agonist ovulation trigger in patients undergoing controlled ovarian hyperstimulation for IVF with ultrashort flare GnRH-agonist combined with multidose GnRH-antagonist protocol. Gynecol Endocrinol. 2013;29(1):51-3.
Orvieto, R., Nahum, R., Zohav, E., Liberty, G., Anteby, E. Y., & Meltcer, S. (2013). GnRH-agonist ovulation trigger in patients undergoing controlled ovarian hyperstimulation for IVF with ultrashort flare GnRH-agonist combined with multidose GnRH-antagonist protocol. Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, 29(1), 51-3. https://doi.org/10.3109/09513590.2012.705376
Orvieto R, et al. GnRH-agonist Ovulation Trigger in Patients Undergoing Controlled Ovarian Hyperstimulation for IVF With Ultrashort Flare GnRH-agonist Combined With Multidose GnRH-antagonist Protocol. Gynecol Endocrinol. 2013;29(1):51-3. PubMed PMID: 22857268.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - GnRH-agonist ovulation trigger in patients undergoing controlled ovarian hyperstimulation for IVF with ultrashort flare GnRH-agonist combined with multidose GnRH-antagonist protocol. AU - Orvieto,Raoul, AU - Nahum,Ravit, AU - Zohav,Efraim, AU - Liberty,Gad, AU - Anteby,Eyal Y, AU - Meltcer,Simion, Y1 - 2012/08/03/ PY - 2012/8/4/entrez PY - 2012/8/4/pubmed PY - 2013/5/29/medline SP - 51 EP - 3 JF - Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology JO - Gynecol Endocrinol VL - 29 IS - 1 N2 - OBJECTIVE: To evaluate, whether Gonadotropin-releasing hormone-agonist (GnRH-agonist or GnRH-ag) trigger in patients undergoing the ultrashort GnRH-ag/GnRH-antagonist (GnRH-ant) protocol is as effective as in patients at high risk to develop severe ovarian hyperstimulation syndrome (OHSS), who undergo the multidose GnRH-ant protocol. DESIGN: Cohort study. SETTING: University hospital. PATIENTS: All consecutive women aged ≤35 years admitted to our IVF unit from January 2011 to October 2011 who reached the ovum pick-up stage. INTERVENTIONS: Triggering final oocytes maturation by GnRH-ag instead of hCG, in high-responder patients undergoing either the ultrashort GnRH-ag/GnRH-ant or the multidose GnRH-antagonist controlled ovarian hyperstimulation (COH) protocols. MAIN OUTCOME MEASURES: Ovarian stimulation characteristics, percentage of mature oocytes, fertilization and pregnancy rates. RESULTS: No inbetween groups differences were observed in ovarian-stimulation related variable, percentage of mature oocytes, fertilization or pregnancy rates. No case of moderate-severe OHSS was reported in the study, or the control groups. CONCLUSIONS: Three consecutive doses of daily GnRH-ag administration at the beginning of ultrashort flare GnRH-ag/GnRH-ant COH protocol, did not interfere with the ability of the GnRH-ag to trigger final oocytes maturation at the end of the COH cycle. SN - 1473-0766 UR - https://www.unboundmedicine.com/medline/citation/22857268/GnRH_agonist_ovulation_trigger_in_patients_undergoing_controlled_ovarian_hyperstimulation_for_IVF_with_ultrashort_flare_GnRH_agonist_combined_with_multidose_GnRH_antagonist_protocol_ L2 - https://www.tandfonline.com/doi/full/10.3109/09513590.2012.705376 DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓3]

Related Citations

More